Evaluación de la presencia de inmunidad humoral específica contra SARS-COV-2 causante del COVID-19 en hombres de la UPS sede Quito en edades superiores a 31 años, posterior al proceso de vacunación

Abstract

After the arrival of the pandemic, a greater susceptibility to COVID-19 has been evidenced in male sex; as time went by, the vaccination process was developed to counteract the effects caused by the virus. It is essential to know the effectiveness of the immunity produced by the administered vaccines, therefore, in the present study the presence of specific humoral immunity against SARS-CoV-2 was evaluated in men from the UPS Quito headquarters over 31 years old, after the vaccination process. For this purpose, the participation of men from the university community in the project was requested and approved by the Ministry of Public Health and the competent authorities. Once the required information had been collected, each participant was given an informed consent form and the rapid COVID-19 antibody test was performed by trained personnel and the results were recorded after 10 minutes. A statistical analysis of correlations in the Infostat software was used to determine the influence of certain parameters on the development of immunity in the study population of 150 volunteers. Based on the humoral immune response, a relationship was obtained between the type of vaccine administered (p=0.0389) and the infection prior to the application of the serological test (p=0.0006). When evaluating the age range and the number of doses used, no relationship was found with the presence or absence of immunity because they presented a p value < 0.05. In virtue of what was studied, when applying a qualitative test, it is recommended to additionally use quantitative antibody tests and antibody neutralization assays to verify the effectiveness of vaccines, contributing to clinical management and public health practice.